Cory Renauer
Value, research analyst, biotech, small-cap

Emergent Biosciences Finally Expanding Beyond Anthrax

Emergent Biosolutions (NYSE:EBS) is a commercial stage biotech that produces the only FDA approved anthrax vaccine. The company derives nearly all of its revenue from sales of BioThrax, its only marketed product, to the US Government. Currently, nearly all of Emergent's revenue comes from a contract with the Centers for Disease Control (NASDAQ:CDC) that ends in September 2016.

To a cautious investor, a company with a single customer is bathed in red light. However, Emergent is attempting a transition. Lets see how its going.

Bracco Acquisition

On August 2, 2013, Emergent finished the acquisition of the Healthcare Protective Products Division (HPPD) from the privately held Italian giant, Bracco Diagnostics. The purchase included FDA approved Reactive Skin...

Join Seeking Alpha PRO to read this archived article and 11,574 other archived articles
WITH SEEKING ALPHA PRO, INVESTORS CAN ALSO:
  • Access Top Ideas, chosen by Seeking Alpha’s editors
  • Filter long and short ideas by market cap and sector
  • Get Coverage of over 5,000 stocks, many of which have little or no coverage elsewhere
"In just the first month of using PRO, I used it to generate two ideas which were actionable for me. As a result of these two positions, I have earned more than 20 times the annual subscription costs for PRO." Michael Yagemann, Greenbridge Capital
"I am pleasantly surprised with the scope of small and mid-cap coverage PRO offers. You can't find that any where else." Patrick Rice, Mainstay Capital Management
100% Satisfaction Guaranteed
Money back guarantee. Seeking Alpha PRO members receive a no-questions-asked refund for membership on months paid and not used. Details